References
- 1. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, et al.; American Heart Association; American Stroke Association. Update to the AHA/ ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008; 39(5): 1647-1652.
- 2. Mukherjee D, Patil CG. Epidemiology and the global burden of stroke. World Neurosurg. 2011; 76(6 Suppl): S85-S90.
- 3. Tousoulis D, Siasos G, Zaromitidou M, Oikonomou E, Maniatis K, Kioufis S, et al. The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel. Int J Cardiol. 2013; 168(2): 1594-1596.
- 4. Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K, Ortak M, et al. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol. 2006; 26(7): 1648-1652
- 5. Chae H, Kim M, Koh YS, Hwang BH, Kang MK, Kim Y, et al. Feasibility of a microarraybased point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity. Biomed Res Int. 2013; 2013: 154073. doi: 10.1155/2013/154073.
- 6. PharmGKB [Internet]. Palo Alto (CA): Stanford University. Gene: CYP2C19. Available from: http://www.pharmgkb.org/gene/PA124. Accessed November 10 2014.
- 7. Scott SA, Sangkuhl K, Gardner EE, Stein CM. Clinical pharmacogenetics implementation consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Parmacol Therapeut. 2011; 90(2): 328-332.
- 8. Kaikita K, Ono T, Iwashita S, Nakayama N, Sato K, Horio E, et al. Impact of CYP2C19 polymorphism on platelet function tests and coagulation and inflammatory biomarkers in patients undergoing percutaneous coronary intervention. J Atheroscler Thromb. 2014; 21(1): 64-76.
- 9. Kim KA, Song WG, Lee HM, Joo HJ, Park JY. Effect of P2Y1 and P2Y12 genetic polymorphisms on the ADP-induced platelet aggregation in a Korean population. Thromb Res. 2013; 132(2): 221-226.
- 10. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000; 84(5): 891-896.
- 11. Savi P, Laplace MC, Maffrand JP, Herbert JM. Binding of [3H]-2methylthio ADP to rat platelets - Effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther. 1994; 269(2): 772-777.
- 12. Feng D, Lindpaintner K, Larson MG, Rao VS, O’Donnell CJ, Lipinska I, et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: The Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 1999; 19(4): 1142-1147.
- 13. Lordkipanidze M, Diodati JG, Palisaitis DA, Schampaert E, Turgeon J, Pharand C. Genetic determinants of response to aspirin: Appraisal of 4 candidate genes. Thromb Res. 2011; 128(1): 47-53
- 14. Ziegler S, Schillinger M, Funk M, Felber K, Exner M, Mlekusch W, et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke. 2005; 36(7): 1394-1399.
- 15. Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, et al. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects. Arch Cardiovasc Dis. 2013; 106(10): 517-527.
- 16. Tang XF, Zhang JH, Wang J, Han YL, Xu B, Qiao SB, et al. Effects of coexisting polymorphisms of CYP2 C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention. Chin Med J (Engl). 2013; 126(6): 1069-1075.
- 17. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk for ischemic events (CAPRIE). Lancet. 1996; 348 (9038): 1329-1339.
- 18. Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol. 2003; 91(9): 1123-1125.
- 19. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003; 107(23): 2908-2913.
- 20. Spokoyny I, Barazangi N, Jaramillo V, Rose J, Chen C, Wong C, et al. Reduced clopidogrel metabolism in a multiethnic population: Prevalence and rates of recurrent cerebrovascular events. J Stroke Cerebrovasc Dis. 2014; 23(4): 694-698.
- 21. Anderson CD, Biffi A, Greenberg SM, Rosand J. Personalized approaches to clopidogrel therapy: Are we there yet? Stroke. 2010; 41(12): 2997-3002.
- 22. US Food and Drug Administration. Clopidogrel black box warning. Available from: http:// www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm203888.htm. Accessed November 10, 2014.
- 23. Terpening C. Clopidogrel: A pharmacogenomic perspective on its use in coronary artery disease. Clin Med Insights Cardiol. 2010; 4(1): 117-128.